News | April 06, 2022
Revenue growth to moderate, non-Covid-19 revenue to drive profitability
Ind-Ra maintains a neutral outlook for healthcare in FY23
Ind-Ra maintains a neutral outlook for healthcare in FY23
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
The new facility is scheduled to start operation in the first half of 2024
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
It also secures US $ 10 million for US launch and commercialization
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Subscribe To Our Newsletter & Stay Updated
